L. White

A phase I study to assess the single and multiple dose pharmacokinetics of THC/CBD oromucosal spray

G. Guy, D. Wilbraham, S. Wright, 2012, European Journal of Clinical Pharmacology.

Pharmacokinetics and Disposition

G. Guy, D. Wilbraham, S. Wright, 2022 .

A Multiple‐Dose, Randomized, Double‐Blind, Placebo‐Controlled, Parallel‐Group QT/QTc Study to Evaluate the Electrophysiologic Effects of THC/CBD Spray

E. Sellers, P. Duncombe, Chien-Feng Chen, 2013, Clinical pharmacology in drug development.

A Phase I, open-label, randomized, crossover study in three parallel groups to evaluate the effect of Rifampicin, Ketoconazole, and Omeprazole on the pharmacokinetics of THC/CBD oromucosal spray in healthy volunteers

G. Guy, D. Wilbraham, S. Wright, 2013, SpringerPlus.

A randomized, double‐blind, placebo‐controlled, crossover study to evaluate the subjective abuse potential and cognitive effects of nabiximols oromucosal spray in subjects with a history of recreational cannabis use

E. Sellers, G. Guy, M. Romach, 2011, Human psychopharmacology.

P.6.c.010 Abuse potential of nabiximols oromucosal spray compared with dronabinol and placebo in recreational marijuana users

E. Sellers, G. Guy, S. Wright, 2010, European Neuropsychopharmacology.

Pharmacokinetics and Disposition

G. Guy, D. Wilbraham, S. Wright, 2022 .